Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

A lead-optimization stage biopharma­ceutical company We are working on a first-in-class series of anti-cancer molecules that reactivate a key tumor suppressor, protein phosphatase 2A (PP2A). Rappta's proprietary tools and understanding of the target allow us to therapeutically reactivate PP2A, a critical enzyme regulating protein de-phosphorylation and tumor growth.

List your booth number for exhibitions, ask us